High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement
Systemic non-Hodgkin lymphoma with synchronous central nervous system involvement traditionally carries a poor prognosis. We found encouraging results with the use of high-dose chemotherapy and autologous stem cell transplantation as consolidation for patients in first complete remission. Central nervous system-directed conditioning with a thiotepa-based regimen might reduce the incidence of relapse and improve the outcomes in this population.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: David Qualls, Andrew Sullivan, Shuli Li, Andrew M. Brunner, Kerry Collier, Ephraim Hochberg, Philippe Armand, Tracy T. Batchelor, Yi-Bin Chen, Zachariah DeFilipp Tags: Original Study Source Type: research
More News: Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Stem Cell Therapy | Stem Cells | Study | Transplants